Rapid communication Open Access
Like 0


We monitored antimicrobial susceptibility developments of in Germany from January 2014 to May 2021. The proportion of isolates with azithromycin minimum inhibitory concentrations above the epidemiological cut-off increased substantially, from 1.3% in 2014 to 12.2% in 2020. Preliminary data from 2021 showed a further rise (January to May: 20.7%). Therefore, azithromycin as part of the recommended dual therapy in Germany for non-adherent patients is challenged. Antimicrobial susceptibility testing in clinical practice is crucial and continuous susceptibility surveillance indispensable.


Article metrics loading...

Loading full text...

Full text loading...



  1. Buder S, Dudareva S, Jansen K, Loenenbach A, Nikisins S, Sailer A, et al. Antimicrobial resistance of Neisseria gonorrhoeae in Germany: low levels of cephalosporin resistance, but high azithromycin resistance. BMC Infect Dis. 2018;18(1):44.  https://doi.org/10.1186/s12879-018-2944-9  PMID: 29343220 
  2. Unemo M, Golparian D, Sánchez-Busó L, Grad Y, Jacobsson S, Ohnishi M, et al. The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization. J Antimicrob Chemother. 2016;71(11):3096-108.  https://doi.org/10.1093/jac/dkw288  PMID: 27432602 
  3. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints - bacteria (v 11.0). Växjö: EUCAST; 2021. Available from: https://www.eucast.org/clinical_breakpoints
  4. European Centre for Disease Prevention and Control (ECDC). Gonococcal antimicrobial susceptibility surveillance in Europe – Results summary 2018. Stockholm: ECDC; 2020. Available from: https://www.ecdc.europa.eu/en/publications-data/gonococcal-antimicrobial-susceptibility-surveillance-europe-2018
  5. European Centre for Disease Prevention and Control (ECDC). Response plan to control and manage the threat of multi- and extensively drug-resistant gonorrhoea in Europe. Stockholm: ECDC; 2019. Available from: https://www.ecdc.europa.eu/en/publications-data/response-plan-control-and-manage-threat-multi-and-extensively-drug-resistant
  6. Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014;27(3):587-613.  https://doi.org/10.1128/CMR.00010-14  PMID: 24982323 
  7. Deutsche STI-Gesellschaft, Deutsche AIDS-Gesellschaft, Deutsche Gesellschaft für Urologie, Deutsche Dermatologische Gesellschaft, Deutsche Gesellschaft für Andrologie, Deutsche Gesellschaft für Gynäkologie und Geburtshilfe, et al. Diagnostik und Therapie der Gonorrhoe. S2k-Leitlinie: Registernummer 059-004. [Diagnostics and therapy of gonorrhoea. Guideline S2k, register number 059-004]. Düsseldorf: Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V.; 2018. German. Available from: https://www.awmf.org/leitlinien/detail/ll/059-004.html
  8. Unemo M, Ross J, Serwin AB, Gomberg M, Cusini M, Jensen JS. 2020 European guideline for the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2020;956462420949126.  https://doi.org/10.1177/0956462420949126  PMID: 33121366 
  9. Unemo M, Workowski K. Dual antimicrobial therapy for gonorrhoea: what is the role of azithromycin? Lancet Infect Dis. 2018;18(5):486-8.  https://doi.org/10.1016/S1473-3099(18)30162-2  PMID: 29523498 
  10. Fifer H, Cole M, Hughes G, Padfield S, Smolarchuk C, Woodford N, et al. Sustained transmission of high-level azithromycin-resistant Neisseria gonorrhoeae in England: an observational study. Lancet Infect Dis. 2018;18(5):573-81.  https://doi.org/10.1016/S1473-3099(18)30122-1  PMID: 29523496 
  11. Salmerón P, Viñado B, Arando M, Alcoceba E, Romero B, Menéndez B, et al. Neisseria gonorrhoeae antimicrobial resistance in Spain: a prospective multicentre study. J Antimicrob Chemother. 2021;76(6):1523-31.  https://doi.org/10.1093/jac/dkab037  PMID: 33569588 
  12. Salmerón P, Moreno-Mingorance A, Trejo J, Amado R, Viñado B, Cornejo-Sanchez T, et al. Emergence and dissemination of three mild outbreaks of Neisseria gonorrhoeae with high-level resistance to azithromycin in Barcelona, 2016-18. J Antimicrob Chemother. 2021;76(4):930-5.  https://doi.org/10.1093/jac/dkaa536  PMID: 33367806 
  13. Buder S, Heuer D, Guhl E, Graeber I, Eicke S, Obermeier M, et al. Gonorrhö mit einem high-level-Azithromycin-resistenten Erreger in Deutschland. [Gonorrhea with a high-level azithromycin-resistant pathogen in Germany]. Epid Bull. 2019;32(33):299-300. German.  https://doi.org/http://dx.doi.org/10.25646/6211 
  14. Berçot B, Belkacem A, Goubard A, Mougari F, Sednaoui P, La Ruche G, et al. High-level azithromycin-resistant Neisseria gonorrhoeae clinical isolate in France, March 2014. Euro Surveill. 2014;19(44):20951.  https://doi.org/10.2807/1560-7917.ES2014.19.44.20951  PMID: 25394255 
  15. Lahra MM, Hogan TR, Shoushtari M, Armstrong BH. Australian Gonococcal Surveillance Programme Annual Report, 2020. Commun Dis Intell (2018). 2021;45.  https://doi.org/10.33321/cdi.2021.45.24  PMID: 33934693 
  16. Holderman JL, Thomas JC, Schlanger K, Black JM, Town K, Cyr SB, et al. Sustained transmission of Neisseria gonorrhoeae with high-level resistance to Azithromycin, Indianapolis, Indiana 2017-2018. Clin Infect Dis. 2021;ciab132.  https://doi.org/10.1093/cid/ciab132  PMID: 33581693 
  17. Banhart S, Selb R, Oehlmann S, Bender J, Buder S, Jansen K, et al. The mosaic mtr locus as major genetic determinant of azithromycin resistance of Neisseria gonorrhoeae, Germany, 2018. J Infect Dis. 2021;jiab091.  https://doi.org/10.1093/infdis/jiab091  PMID: 33592101 
  18. Valsesia G, Hombach M, Maurer FP, Courvalin P, Roos M, Böttger EC. The resistant-population cutoff (RCOFF): a new concept for improved characterization of antimicrobial susceptibility patterns of non-wild-type bacterial populations. J Clin Microbiol. 2015;53(6):1806-11.  https://doi.org/10.1128/JCM.03505-14  PMID: 25762769 

Data & Media loading...

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error